Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

502 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop.
Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA Jr. Jarow JP, et al. Among authors: sartor o. Urology. 2014 May;83(5):975-8. doi: 10.1016/j.urology.2013.10.087. Epub 2014 Mar 22. Urology. 2014. PMID: 24661332
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C; Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Carroll PR, et al. Among authors: sartor o. Urology. 2002 Sep;60(3 Suppl 1):1-6. doi: 10.1016/s0090-4295(02)01559-5. Urology. 2002. PMID: 12231036 Review. No abstract available.
Endpoints in prostate cancer clinical trials.
Sartor O. Sartor O. Urology. 2002 Sep;60(3 Suppl 1):101-7; discussion 107-8. doi: 10.1016/s0090-4295(02)01585-6. Urology. 2002. PMID: 12231062 Review.
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D. Eisenberger MA, et al. Among authors: sartor o. Urology. 2004 Jan;63(1):114-9. doi: 10.1016/j.urology.2003.08.017. Urology. 2004. PMID: 14751361 Clinical Trial.
502 results